All Articles

TotalEnergies is creating the UK's largest independent oil producer. A bold bet on fossil fuel efficiency or a contradiction to its green energy goals?

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

Bowman Consulting's acquisition of RPT Alliance is a strategic move to solve the energy crisis facing AI and data centers with rapid-deployment power.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

OSE Immunotherapeutics is taking back a key drug from AbbVie, betting its own cash on a bigger prize. What does this strategic pivot reveal about pharma R&D?

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Fresh off its spin-off, the US metals processor is in talks to acquire a German giant, a move that could reshape the global steel industry.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A new report shows Business Development Companies are stable, but look closer: dividend pressures and softening credit quality reveal a widening gap.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

AMC sells its Hycroft Mining stake to gold titan Eric Sprott for $24.1M, ending a curious diversification to double down on its core cinema business.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

A junior miner's auditor and finance chief changes signal a calculated move to de-risk its path to becoming a major developer of a 'green' gold mine.

With shareholder approval secured, the HNI-Steelcase merger is set to create a $5.8B powerhouse. But can it deliver on its $120M synergy promise?

While the design world embraces white, one company is investing in a full-spectrum color technology, building a resilient market niche.

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.

A Carroll, Ohio firm keeps winning top awards for managing wealth. We explore how its strategies are enabling affluent retirees to navigate uncertainty.